<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846895</url>
  </required_header>
  <id_info>
    <org_study_id>303/16-04-2018</org_study_id>
    <nct_id>NCT03846895</nct_id>
  </id_info>
  <brief_title>Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)</brief_title>
  <official_title>The Role of the Micro-ablative Fractional CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical efficacy and symptom relief of vaginal fractional CO2 laser
      treatment in post-menopausal women with Overactive Bladder syndrome(OAB). Post-menopausal
      women with OAB syndrome who receive β3 adrenergic receptors (mirabegron 50mg) treatment, will
      be randomized in two groups. Half participants will receive active CO2 laser therapy, while
      the other half will receive placebo CO2 laser therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2018</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overactive Bladder questionaire (OAB-q)</measure>
    <time_frame>24 months</time_frame>
    <description>It consists of an 8 item symptom bother scale section and a 25 item health related quality of life scale section (HRQL). Scores of each domain of the 2 sections range from 0 to 100. Higher scores indicate higher impact of overactive bladder symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3 days voiding diary</measure>
    <time_frame>24 months</time_frame>
    <description>Assesses bladder function (frequency of micturition, urgency and urinary incontinence)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>King's Health Questionnaire (KHQ)</measure>
    <time_frame>24 months</time_frame>
    <description>It has 3 sections: 1) general health and overall health related to urinary symptoms with 2 questions, 2) incontinence impact, role limitations, physical limitations, social limitations, personal limitations, emotions, sleep and energy, and severity coping measures with 19 questions and 3) bother or impact of urinary symptoms with 11 questions. Scores of each domain of the 2 sections range from 0 to 100. Scores of the third section range from 0 to 3. Higher scores indicate higher impact of urinary incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Global Impression of Improvement (PGI-I)</measure>
    <time_frame>24 months</time_frame>
    <description>It is a single question with 7 possible answers. Patients will chose the answer that applies at their impression of improvement after the laser therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urogenital Distress Inventory questionaire (UDI-6)</measure>
    <time_frame>24 months</time_frame>
    <description>It is a 6 item questionaire evaluating symptom distress of urinary incontinence and its impact on daily life. Scores range from 0 to 100. Higher scores indicate higher impact of urinary incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Impact Questionnaire—short form 7 (PFIQ-7)</measure>
    <time_frame>24 months</time_frame>
    <description>It is a 7 item questionaire evaluating how much bladder symptoms affect their activities, relationships, and feelings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Overactive Bladder (OAB)</condition>
  <arm_group>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microablative Fractional CO2 laser therapy at monthly intervals.
The laser parameters that will be used are the following:
Power: 40 watts,
Dwell time:1000μs,
Spacing 1000 μm,
Depth: SmartStak parameter 3
D-pulse mode.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo CO2 laser therapies at monthly intervals.
The laser parameters that will be used are the following:
Power: 0.5 watts,
Dwell time:1000μs,
Spacing 1000 μm,
Depth: SmartStak parameter 1,
Smart-pulse mode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microablative Fractional CO2 laser</intervention_name>
    <description>3 therapies intravaginally administered will be applied at monthly intervals</description>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>SmartXide2 V2LR, Monalisa Touch, DEKA, Florence, Italy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (≥ 12 months of amenorrhea or FSH ≥ 40 after hysterectomy with
             bilateral oophorectomy) who receive β3 adrenergic receptors (mirabegron 50 mg)
             treatment for OAB

          -  Overactive bladder syndrome (OAB)

               -  ≥ 3 months symptoms of urgency, with or without urinary incontinence, and ≥ 8
                  micturitions / 24h

               -  At least 3 episodes of urgent urination (3rd-4th grade) as recorded in the
                  patient perception intensity of urgency scale (PPiUS) during a 3 day urination
                  calendar , with or without urinary incontinence.

        Exclusion Criteria:

          -  Participants with:

               -  Pelvic Organ Prolapse (POP) &gt; stage II of the pelvic organ prolapse quantitation
                  system (POP-Q)

               -  Post void residual volume &gt; 200 ml (measured by ultrasound)

               -  Use of moisturizers or lubricants the last month

               -  Use of vaginal estrogen in the last 6 months

               -  Use of drugs for urinary incontinence

               -  Use of psychotropic drugs

               -  Symptomatic urinary tract infection

               -  Active genital infection

               -  Kidney or liver disease

               -  Abnormal cardiac conduction, rate or rythm disorders

               -  Diabetic neuropathy

               -  Myasthenia gravis

               -  History of malignant disease

               -  Previous radio-chemo therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Themos Grigoriadis, Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stavros Athanasiou, Associate Professor</last_name>
    <phone>+306944478555</phone>
    <email>stavros.athanasiou@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konstantinos Kypriotis, MD</last_name>
    <phone>+306946150887</phone>
    <email>kypriotisk@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urogynecological Unit of Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stavros Athanasiou, Prof.</last_name>
      <phone>+306944478555</phone>
      <email>stavros.athanasiou@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Themos Grigoriadis, Assist. Prof.</last_name>
      <phone>+306948741306</phone>
      <email>tgregos@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stavros Athanasiou, Associate Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Themos Grigoriadis, Assistant Proffesor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Kypriotis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Themos Grigoriadis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

